As 2025 draws to a close, it’s evident that legendary investor Warren Buffett underperformed the S&P 500 during his last year as CEO of Berkshire Hathaway Inc (NYSE:BRK)(NYSE:BRK).Several stocks in the Berkshire Hathaway portfolio have underperformed the market this year, including Pool Corp (NASDAQ:POOL), one of the newer picks from the Buffett-led conglomerate.Pool Corp Stock StrugglesIn the second quarter of 2025, Berkshire's 13F filing revealed that Buffett and his team of investors increased their posi ...

Eli Lilly and Company (LLY), headquartered in Indianapolis, Indiana, is a leading global pharmaceutical company dedicated to developing innovative treatments for diseases such as diabetes, obesity, Alzheimer’s disease, cancer, and autoimmune disorders. Founded in 1876, the company combines biotechnology, chemistry, and genetic medicine to improve health worldwide. Recently, Lilly announced an investment of over $1 billion to expand manufacturing and supply capabilities in India, reinforcing its commitment ...

Core Viewpoint - Amazon has underperformed compared to the S&P 500 over the past five years, with a total gain of approximately 56% versus the S&P 500's 112% return [1][2]. Performance Context - The performance of Amazon should be viewed in the context of the COVID-19 pandemic, which significantly boosted e-commerce demand in 2020 [4][6]. - From the beginning of 2020 to mid-September 2020, Amazon's stock rose by 63%, while the S&P 500 only gained 5% during the same period [6]. Comparative Analysis - Despite the recent underperformance, Amazon has outperformed the S&P 500 by about 26 percentage points when comparing the period from the beginning of 2020 to the present [7].

Core Insights - Moderna Inc. (MRNA) stock dropped 7% following a report linking the deaths of 25 children to COVID-19 vaccines, resulting in a year-to-date decline of almost 45% [2] - MRNA's performance is being compared to its peers to assess whether its decline is an outlier or part of a broader trend [5] Financial Performance - MRNA's operating margin is -107.1%, the lowest among its peers, while Pfizer (PFE) has an operating margin of 26.1% [8] - MRNA's last-twelve-month revenue growth is -38.8%, underperforming compared to PFE, Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), AbbVie (ABBV), and Amgen (AMGN) [8] - Over the past year, MRNA's stock has decreased by 66.3% and currently trades at a price-to-earnings (P/E) ratio of -3.1, indicating a loss [8] Competitive Context - MRNA has 44 programs, including 26 clinical trials across various therapeutic areas, which include infectious diseases and immuno-oncology [4] - The recent performance of MRNA, including a 12.6% decline over the last month, raises questions about its valuation and fundamentals in comparison to its competitors [5][8]